secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-097860
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical Q3 revenue falls to $56K; FDA OKs pivotal trial for Acclaim CI
----------------------------------------------------------------------------

- Net revenues $56K for Q3 2024, down 30% from $80K in Q3 2023; nine-month revenues $183K, down 17%.
- Cash and cash equivalents $4.4M as of Sep 30, 2024, with R&D expenses up 47% to $2.8M due to clinical prep for Acclaim CI.
- FDA approved initiation of pivotal clinical study for fully implanted Acclaim Cochlear Implant (investigational, Breakthrough Device).
- AMA CPT Editorial Panel approved Category III CPT codes for totally implantable middle ear hearing devices (support for Esteem FI-AMEI reimbursement).
- Bipartisan House and Senate bills introduced to change CMS classification for fully implanted middle ear hearing devices for Medicare coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024097860/0001213900-24-097860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024097860/ea0221085-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer